ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.

85,013 comparisons

Most participants first33,758 with no events in either group come last21 to 40 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Participants Exposed to OACs vs Participants Unexposed to OACs: Number of Participants With Risk of Falls in Non-valvular AF Participants Exposed to OAC and Unexposed to OAC186,288 of 485,646

170,465 of 332,236

-12.9 points

-13.2 to -12.7

817,882NCT05838664

A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France

Cases vs Controls: Number of Participants With Diagnosis of Pulmonary Embolism After the Start of Follow-up for Each Person797 of 150,975

2,942 of 603,770

0.0 points

0.0 to 0.1

754,745NCT04969653

The Incidence of Venous Thromboembolism in Atopic Dermatitis

Cases vs Controls: Number of Participants With Diagnosis of Venous Thromboembolism After the Start of Follow-up for Each Person.2,576 of 150,975

7,563 of 603,770

0.5 points

0.4 to 0.5

754,745NCT04969653

The Incidence of Venous Thromboembolism in Atopic Dermatitis

Cases vs Controls: Number of Participants With Diagnosis of Deep-vein Thrombosis After the Start of Follow-up for Each Person1,887 of 150,975

4,934 of 603,770

0.4 points

0.4 to 0.5

754,745NCT04969653

The Incidence of Venous Thromboembolism in Atopic Dermatitis

Flublok Recipients vs SD-IIV Recipients: Number of Adults 50-64 Years Old With Influenza-Like Illness (ILI)1,826 of 279,400

2,871 of 395,852

-0.1 points

-0.1 to -0.0

675,252NCT03694392

Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years

Flublok Recipients vs SD-IIV Recipients: Number of Adults 50-64 Years Old With Polymerase-chain Reaction (PCR) Confirmed Influenza Tests559 of 279,400

925 of 395,852

-0.0 points

-0.1 to -0.0

675,252NCT03694392

Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years

Flublok Recipients vs SD-IIV Recipients: Number of Adults 50-64 Years Old With Polymerase-chain Reaction (PCR) Confirmed Influenza B Tests37 of 279,400

64 of 395,852

-0.0 points

-0.0 to 0.0

675,252NCT03694392

Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years

Flublok Recipients vs SD-IIV Recipients: Number of Adults 50-64 Years Old Hospitalized With Community-acquired Pneumonia106 of 279,400

183 of 395,852

-0.0 points

-0.0 to 0.0

675,252NCT03694392

Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years

Flublok Recipients vs SD-IIV Recipients: Number of Adults 50-64 Years Old Hospitalized With PCR-confirmed Influenza95 of 279,400

153 of 395,852

-0.0 points

-0.0 to 0.0

675,252NCT03694392

Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years

Flublok Recipients vs SD-IIV Recipients: Number of Adults 50-64 Years Old With All-Cause-Hospitalizations4,308 of 279,400

6,005 of 395,852

0.0 points

-0.0 to 0.1

675,252NCT03694392

Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years

Flublok Recipients vs SD-IIV Recipients: Number of Adults 50-64 Years Old With All-Cause Mortality286 of 279,400

422 of 395,852

-0.0 points

-0.0 to 0.0

675,252NCT03694392

Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years

Flublok Recipients vs SD-IIV Recipients: Number of Adults 50-64 Years Old Hospitalized With Cardio-respiratory Events631 of 279,400

890 of 395,852

0.0 points

-0.0 to 0.0

675,252NCT03694392

Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years

Flublok Recipients vs SD-IIV Recipients: Number of Adults 50-64 Years Old With Polymerase-chain Reaction (PCR) Confirmed Influenza A Tests522 of 279,400

862 of 395,852

-0.0 points

-0.1 to -0.0

675,252NCT03694392

Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years

Cases vs Controls: Number of Female Participants With Diagnosis of Risk of Venous Thromboembolism After the Start of Follow-up for Each Person1,506 of 89,093

4,393 of 356,311

0.5 points

0.4 to 0.6

445,404NCT04969653

The Incidence of Venous Thromboembolism in Atopic Dermatitis

Cases vs Controls: Number of Participants Aged 18-44 With Diagnosis of Venous Thromboembolism After the Start of Follow-up for Each Person503 of 84,253

1,592 of 337,007

0.1 points

0.1 to 0.2

421,260NCT04969653

The Incidence of Venous Thromboembolism in Atopic Dermatitis

PCV13-vaccinated Participants vs Unvaccinated Participants: PCV13 Vaccine Effectiveness (VE) for First Event of Invasive Pneumococcal Disease (IPD): Overall Follow-up167 of 85,584

747 of 320,959

-0.0 points

-0.1 to -0.0

406,543NCT05794191

A Study To Learn About The Effects Of Pneumococcal Vaccine In People With HIV

PCV13-vaccinated Participants vs Unvaccinated Participants: PCV13 VE for First Event of Pneumococcal Pneumonia (PP): Overall Follow-up309 of 85,487

1,362 of 320,959

-0.1 points

-0.1 to -0.0

406,446NCT05794191

A Study To Learn About The Effects Of Pneumococcal Vaccine In People With HIV

PCV13-vaccinated Participants vs Unvaccinated Participants: PCV13 VE for First Event of All-cause Pneumonia (ACP): Overall Follow-up8,098 of 80,591

34,498 of 320,959

-0.7 points

-0.9 to -0.5

401,550NCT05794191

A Study To Learn About The Effects Of Pneumococcal Vaccine In People With HIV

PCV13-vaccinated Participants vs Unvaccinated Participants: VE for First Event of IPD at 0-3 Years of Follow-up73 of 75,382

566 of 320,959

-0.1 points

-0.1 to -0.1

396,341NCT05794191

A Study To Learn About The Effects Of Pneumococcal Vaccine In People With HIV

PCV13-vaccinated Participants vs Unvaccinated Participants: VE for First Event of PP at 0-3 Years of Follow-up161 of 75,322

1,092 of 320,959

-0.1 points

-0.2 to -0.1

396,281NCT05794191

A Study To Learn About The Effects Of Pneumococcal Vaccine In People With HIV

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=2

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT05838664-fd3e43f4",
        "title": "Participants Exposed to OACs vs Participants Unexposed to OACs: Number of Participants With Risk of Falls in Non-valvular AF Participants Exposed to OAC and Unexposed to OAC",
        "summary": "186288 of 485646 against 170465 of 332236; risk difference -12.9 points, 95% interval -13.2 to -12.7; NCT05838664, A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France",
        "record": "/library/comparisons/NCT05838664-fd3e43f4",
        "nct_id": "NCT05838664",
        "kind": "outcome",
        "participants": 817882,
        "risk_difference": {
          "value": -0.1294960271540792,
          "lower": -0.13167681979414997,
          "upper": -0.12731384426530135
        },
        "group_1": "186,288 of 485,646",
        "group_2": "170,465 of 332,236",
        "difference": "-12.9 points",
        "interval": "-13.2 to -12.7",
        "trial_title": "A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France"
      },
      {
        "id": "NCT04969653-94fcfe1e",
        "title": "Cases vs Controls: Number of Participants With Diagnosis of Pulmonary Embolism After the Start of Follow-up for Each Person",
        "summary": "797 of 150975 against 2942 of 603770; risk difference 0.0 points, 95% interval 0.0 to 0.1; NCT04969653, The Incidence of Venous Thromboembolism in Atopic Dermatitis",
        "record": "/library/comparisons/NCT04969653-94fcfe1e",
        "nct_id": "NCT04969653",
        "kind": "outcome",
        "participants": 754745,
        "risk_difference": {
          "value": 0.00040630327349540016,
          "lower": 0.00001045503636930078,
          "upper": 0.0008221125366069937
        },
        "group_1": "797 of 150,975",
        "group_2": "2,942 of 603,770",
        "difference": "0.0 points",
        "interval": "0.0 to 0.1",
        "trial_title": "The Incidence of Venous Thromboembolism in Atopic Dermatitis"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=3",
  "request_id": "XXTsAvq-NBAT6JP8"
}
trial-comparisons-2026-03-23-0.1.0Next page

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Open193,990 genes2026-11-11

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Open611,552 trials2026-11-12

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

For invited accounts.

Opens sequences.conductscience.org

By invitation39,249,078 sequences2026-11-05

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?